J&J Bounces Back In Q3, Led By Interventional Devices
Johnson & Johnson’s worldwide medical device revenues grew about 50% sequentially in the third quarter to $6.2bn.
You may also be interested in...
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.
COVID-19 Medtech Lessons: Data Point To ‘Healthy Industry In An Unhealthy Time’ But Business Models Must Change
Ernst &Young’s annual Pulse of the Industry report says strong R&D spending by medtechs in 2019 bodes well for their post-pandemic recovery as industry leaders point to long-term changes to the industry that companies must navigate when future-proofing their business models.
Hospitals’ budgets for capital equipment have been strained during the pandemic, but they will continue to invest in digital surgery and robotics because the technologies offer value to patients, according to executives at The Virtual MedTech Conference.